Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | GRM5 | P41594 | 8/20 | 0.68 |
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | AGER | Q15109 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15045370 | 0.86 | NPC1 (0.70) | POLBGRM5NPC1RAB9AMAPT | |
| SCHEMBL15043007 | 0.83 | MAPT (0.66) | MEN1POLBKMT2AGRM5NPC1 | |
| SCHEMBL9963860 | 0.82 | GRM5 (0.75) | GRM5NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL13296220 | 0.81 | GRM5 (0.82) | POLBKMT2AGRM5NPC1RAB9A | |
| SCHEMBL10804342 | 0.79 | NPC1 (0.57) | MEN1POLBKMT2AGRM5NPC1 | |
| SCHEMBL8170829 | 0.78 | GRM5 (0.73) | GRM5NPC1RAB9A | |
| SCHEMBL8557860 | 0.77 | GRM5 (1.00) | GRM5NPC1RAB9A | |
| SCHEMBL2624735 | 0.77 | FOXO1 (0.57) | MEN1POLBKMT2ANPC1RAB9A | |
| SCHEMBL10810757 | 0.77 | NPC1 (0.55) | MEN1POLBKMT2AGRM5NPC1 | |
| SCHEMBL23367929 | 0.77 | GRM5 (0.75) | POLBKMT2AGRM5NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160166553-A1 | ANTIMETASTATIC COMPOUNDS | UNIV BRIGHAM YOUNG (US) | 2016-06-16 | — | — | US | disclosed |
| US-20130158035-A1 | ANTIMETASTATIC COMPOUNDS | BRIGHAM YOUNG UNIVERSITY (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158035-A1 | ANTIMETASTATIC COMPOUNDS | MET, HGFAC, HGF | MEN1 391/4885POLB 3043/4885KMT2A 3928/4885 |
| US-20160166553-A1 | ANTIMETASTATIC COMPOUNDS | MET, HGFAC, HGF | MEN1 391/4885POLB 3043/4885KMT2A 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.